Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with Type 2 Diabetes (T2DM): Pooled data from four pivotal phase III trials

Background, methods: We analyzed pooled data from 2477 patients with T2DM (mean [SD] age 55.6 [10.2] years, HbA1c 7.99 [0.85]%, BMI 28.7 [5.5] kg/m2) from four randomized, placebo-controlled Phase III trials that investigated empagliflozin (EMPA) 10 mg or 25 mg given for 24 weeks as monotherapy, add-on to metformin (MET), add-on to MET + SU, or add-on to pioglitazone ± MET. Results: EMPA significantly reduced HbA1c (in %; EMPA 10 mg: -0.70, EMPA 25 mg: -0.76, placebo [PBO]: -0.08), fasting plasma glucose (in mg/dL; EMPA 10 mg: -20.5, EMPA 25 mg: -23.2, PBO: +7.4), weight (in kg; EMPA 10 mg: -2.05, EMPA 25 mg: -2…